|
1
|
Greene JM, Schneble EJ, Jackson DO, Hale
DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X,
et al: A phase I/IIa clinical trial in stage IV melanoma of an
autologous tumor-dendritic cell fusion (dendritoma) vaccine with
low dose interleukin-2. Cancer Immunol Immunother. 65:383–392.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagaoka T, Kiyohara Y, Koga H, Nakamura A,
Saida T and Sota T: Modification of a melanoma discrimination index
derived from hyperspectral data: A clinical trial conducted in 2
centers between March 2011 and December 2013. Skin Res Technol.
21:278–283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grob JJ, Amonkar MM, Karaszewska B,
Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K,
Grange F, Chiarion-Sileni V, et al: Comparison of dabrafenib and
trametinib combination therapy with vemurafenib monotherapy on
health-related quality of life in patients with unresectable or
metastatic cutaneous BRAF Val600-mutation-positive melanoma
(COMBI-v): Results of a phase 3, open-label, randomised trial.
Lancet Oncol. 16:1389–1398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mohr P, Hauschild A, Trefzer U, Enk A,
Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, et al:
Intermittent high-dose intravenous interferon alfa-2b for adjuvant
treatment of stage III melanoma: Final analysis of a randomized
phase III dermatologic cooperative oncology group trial. J Clin
Oncol. 33:4077–4084. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varamo C, Occelli M, Vivenza D, Merlano M
and Lo Nigro C: MicroRNAs role as potential biomarkers and key
regulators in melanoma. Genes Chromosomes Cancer. 2016.PubMed/NCBI
|
|
6
|
Li JY, Zheng LL, Wang TT and Hu M:
Functional annotation of metastasis-associated microRNAs of
melanoma: A meta-analysis of expression profiles. Chin Med J.
129:2484–2490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mannavola F, Tucci M, Felici C, Stucci S
and Silvestris F: miRNAs in melanoma: A defined role in tumor
progression and metastasis. Expert Rev Clin Immunol. 12:79–89.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jayawardana K, Schramm SJ, Haydu L,
Thompson JF, Scolyer RA, Mann GJ, Müller S and Yang JY:
Determination of prognosis in metastatic melanoma through
integration of clinico-pathologic, mutation, mRNA, microRNA, and
protein information. Int J Cancer. 136:863–874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aftab MN, Dinger ME and Perera RJ: The
role of microRNAs and long non-coding RNAs in the pathology,
diagnosis, and management of melanoma. Arch Biochem Biophys.
563:60–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meng XX, Yao M, Zhang XD, Xu HX and Dong
Q: ER stress-induced autophagy in melanoma. Clin Exp Pharmacol
Physiol. 42:811–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lima RT, Sousa D, Paiva AM, Palmeira A,
Barbosa J, Pedro M, Pinto MM, Sousa E and Vasconcelos MH:
Modulation of autophagy by a thioxanthone decreases the viability
of melanoma cells. Molecules. 21:pii: E1343. 2016. View Article : Google Scholar
|
|
12
|
Caporali S, Alvino E, Lacal PM, Levati L,
Giurato G, Memoli D, Caprini E, Cappellini GC Antonini and D'Atri
S: Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating
effect of dabrafenib on the invasive behavior of melanoma cells
with acquired resistance to the BRAF inhibitor. Int J Oncol.
49:1164–1174. 2016.PubMed/NCBI
|
|
13
|
Peng Y, Li L, Huang M, Duan C, Zhang L and
Chen J: Angiogenin interacts with ribonuclease inhibitor regulating
PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Cell
Signal. 26:2782–2792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guo Y, Chang H, Li J, Xu XY, Shen L, Yu ZB
and Liu WC: Thymosin alpha 1 suppresses proliferation and induces
apoptosis in breast cancer cells through PTEN-mediated inhibition
of PI3K/Akt/mTOR signaling pathway. Apoptosis. 20:1109–1121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Gao X, Deeb D and Gautam SC:
Oleanane triterpenoid CDDO-Me inhibits Akt activity without
affecting PDK1 kinase or PP2A phosphatase activity in cancer cells.
Biochem Biophys Res Commun. 417:570–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scortegagna M, Ruller C, Feng Y, Lazova R,
Kluger H, Li JL, De SK, Rickert R, Pellecchia M, Bosenberg M, et
al: Genetic inactivation or pharmacological inhibition of Pdk1
delays development and inhibits metastasis of
BrafV600E::Pten−/− melanoma. Oncogene.
33:4330–4339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Song R, Fang X, Wang L, Chen W, Tang
P, Yu B, Sun Y and Xu Q: SBF-1, a synthetic steroidal glycoside,
inhibits melanoma growth and metastasis through blocking
interaction between PDK1 and AKT3. Biochem Pharmacol. 84:172–181.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee SJ, Kim TM, Kim YJ, Jang KT, Lee HJ,
Lee SN, Ahn MS, Hwang IG, Lee S, Lee MH, et al: Phase II trial of
nilotinib in patients with metastatic malignant melanoma harboring
KIT gene aberration: A multicenter trial of Korean Cancer
Study Group (UN10-06). Oncologist. 20:1312–1319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo J, Si L, Kong Y, Flaherty KT, Xu X,
Zhu Y, Corless CL, Li L, Li H, Sheng X, et al: Phase II,
open-label, single-arm trial of imatinib mesylate in patients with
metastatic melanoma harboring c-Kit mutation or
amplification. J Clin Oncol. 29:2904–2909. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R, Jing G, Lv J, Song H, Li C, Wang
X, Xia W, Wu Y, Ren G and Guo W: Interferon-α-2b as an adjuvant
therapy prolongs survival of patients with previously resected oral
muscosal melanoma. Genet Mol Res. 14:11944–11954. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shao H, Cai L, Moller M, Issac B, Zhang L,
Owyong M, Moscowitz AE, Vazquez-Padron R, Radtke F and Liu ZJ:
Notch1-WISP-1 axis determines the regulatory role of mesenchymal
stem cell-derived stromal fibroblasts in melanoma metastasis.
Oncotarget. 7:79262–79273. 2016.PubMed/NCBI
|
|
22
|
Ndoye A and Weeraratna AT: Autophagy - An
emerging target for melanoma therapy. F1000Res pii: F1000 Faculty
Rev-1888. 2016. View Article : Google Scholar
|
|
23
|
Stojcheva N, Schechtmann G, Sass S, Roth
P, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis
FJ, et al: MicroRNA-138 promotes acquired alkylator resistance in
glioblastoma by targeting the Bcl-2-interacting mediator BIM.
Oncotarget. 7:12937–12950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kou Y, Li L, Li H, Tan Y, Li B, Wang K and
Du B: Berberine suppressed epithelial mesenchymal transition
through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma
cells. Biochem Biophys Res Commun. 479:290–296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao G, Han X, Zheng S, Li Z, Sha Y, Ni J,
Sun Z, Qiao S and Song Z: Curcumin induces autophagy, inhibits
proliferation and invasion by downregulating AKT/mTOR signaling
pathway in human melanoma cells. Oncol Rep. 35:1065–1074.
2016.PubMed/NCBI
|
|
26
|
Wei BR, Michael HT, Halsey CH, Peer CJ,
Adhikari A, Dwyer JE, Hoover SB, El Meskini R, Kozlov S, Ohler Z
Weaver, et al: Synergistic targeted inhibition of MEK and dual
PI3K/mTOR diminishes viability and inhibits tumor growth of canine
melanoma underscoring its utility as a preclinical model for human
mucosal melanoma. Pigment Cell Melanoma Res. 29:643–655. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cordón-Barris L, Pascual-Guiral S, Yang S,
Giménez-Llort L, Lope-Piedrafita S, Niemeyer C, Claro E, Lizcano JM
and Bayascas JR: Mutation of the 3-phosphoinositide-dependent
protein kinase-1 (PDK1) substrate-docking site in the developing
brain causes microcephaly with abnormal brain morphogenesis
independently of Akt, leading to impaired cognition and disruptive
behaviors. Mol Cell Biol. pii: MCB.00230-16. 2016. View Article : Google Scholar
|
|
28
|
Guo JP, Coppola D and Cheng JQ: IKBKE
protein activates Akt independent of phosphatidylinositol
3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain
malignant transformation. J Biol Chem. 291:228532016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung Y, Yi YS, Yoo DS, Kim JH, Yang WS,
Lee J, Park KW, Kweon DH, Hong S and Cho JY:
8-(Tosylamino)quinoline inhibits tumour progression through
targeting phosphoinositide-3-kinase/Akt pathway. Pharmazie.
68:146–152. 2013.PubMed/NCBI
|
|
30
|
Medina JR: Selective
3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: Dissecting
the function and pharmacology of PDK1. J Med Chem. 56:2726–2737.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Y, Yang K, Sun X, Fang P, Shi H, Xu J,
Xie M and Li M: MiR-138 suppresses airway smooth muscle cell
proliferation through the PI3K/AKT signaling pathway by targeting
PDK1. Exp Lung Res. 41:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
